Bellerophon Therapeutics (NASDAQ: BLPH)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.540 | -0.590 | -0.0500 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Bellerophon Therapeutics (NASDAQ: BLPH) through any online brokerage.
Other companies in Bellerophon Therapeutics’s space includes: ENDRA Life Sciences (NASDAQ:NDRA), Ekso Bionics Holdings (NASDAQ:EKSO), Bluejay Diagnostics (NASDAQ:BJDX), Aethlon Medical (NASDAQ:AEMD) and Motus GI Hldgs (NASDAQ:MOTS).
The latest price target for Bellerophon Therapeutics (NASDAQ: BLPH) was reported by Jefferies on Tuesday, August 11, 2020. The analyst firm set a price target for 19.00 expecting BLPH to rise to within 12 months (a possible 1523.93% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Bellerophon Therapeutics (NASDAQ: BLPH) is $1.17 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Bellerophon Therapeutics.
Bellerophon Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Bellerophon Therapeutics.
Bellerophon Therapeutics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.